Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Scientific Officer | January 27, 2023 | January 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Solid Biosciences Inc.
Report date January 27, 2023 · Filed January 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,201 |
Reported balance
After 2023-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-01-27 · Exercise / conversion · Acquired 1,233 · Balance 20,201 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively. |
| Common StockSEC Table I · non-derivative | Direct | 19,760 |
Reported balance
After 2023-01-27 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-01-27 · Sale · Disposed 441 · Balance 19,760 F3: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,700 |
Reported balance
After 2023-01-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-27 · Exercise / conversion · Disposed 1,233 · Balance 3,700 F1: Restricted stock units convert into common stock on a one-for-one basis. F4: On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively.
F3: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
F4: On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2023 Filed Jan 31, 2023 21:18 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 1,233 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003085 · doc4.xml · derivative · entry 3 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,700 Underlying: Common Stock · 1,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date. F4 · derivative.expiration_date: On January 27, 2022 (the "Grant Date"), the reporting person was granted 4,933 restricted stock units, vesting in four equal installments on the anniversary of the grant date. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:18 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 441 | $7.49 | $3,303.09 |
DisclosureSEC source: 0000899243-23-003085 · doc4.xml · nonDerivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,760 F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:18 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 1,233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-003085 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 490 shares of common stock and 1,462 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2022 and November 30, 2022, respectively. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 47,555 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001135 · doc4.xml · derivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,555 Underlying: Common Stock · 47,555 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:46 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 95,110 | $0.00 Strike: $5.62 | $0.00 |
DisclosureSEC source: 0000899243-23-001135 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,110 Underlying: Common Stock · 95,110 shares Expires 2033-01-03 F1 · derivative.exercise_date: This option was granted on January 3, 2023 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 296,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001209191-22-027118 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,000 Underlying: Common Stock · 296,000 shares Expires 2032-05-02 F1 · derivative.exercise_date: This option was granted on May 2, 2022 and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 17:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,396 | $1.10 | $12,535.60 |
DisclosureSEC source: 0001209191-22-018885 · doc4.xml · nonDerivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,209 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 17:14 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,269 | $1.10 | $12,395.90 |
DisclosureSEC source: 0001209191-22-018885 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,605 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). F2 · balance_after: Includes 2,272 shares acquired by Mr. Morris under the Solid Biosciences Employee Stock Purchase Plan on November 30, 2021. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:34 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005693 · doc4.xml · derivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock. F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:34 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 148,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-22-005693 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,000 Underlying: Common Stock · 148,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,699 | $8.85 | $103,488.18 |
DisclosureSEC source: 0001209191-21-020433 · doc4.xml · nonDerivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,602 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 15, 2020. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 11,699 | $8.84 | $103,458.94 |
DisclosureSEC source: 0001209191-21-020433 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,301 F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 15, 2020. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 16:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,459 | $6.14 | $21,237.91 |
DisclosureSEC source: 0001209191-21-006068 · doc4.xml · nonDerivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,000 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 16:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006068 · doc4.xml · derivative · entry 3 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 16:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-006068 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 16:00 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-005638 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2031-01-25 F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 17:37 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 3,591 | $2.42 | $8,689.14 |
DisclosureSEC source: 0001209191-20-043961 · doc4.xml · nonDerivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,959 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 17:37 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043961 · doc4.xml · derivative · entry 3 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date Read SEC document |
| July 27, 2020 Filed Jul 29, 2020 17:37 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-043961 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 18:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037691 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,050 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest in two equal installments with the first fifty percent vesting on March 11, 2021 and the second fifty percent on March 11, 2022. Read SEC document |
| March 11, 2020 Filed Mar 13, 2020 16:49 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018909 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,050 F1 · shares: The reported transaction is a grant of restricted stock units representing 75,000 shares of common stock. This grant will vest evenly over 2 years with the first fifty percent vesting on the first anniversary of the grant date and the second fifty percent vesting on the second anniversary of the grant date. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 17:34 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Unit · Derivative | 23,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005410 · doc4.xml · derivative · entry 2 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-01-27 F2 · derivative.exercise_date: The restricted stock units will vest in 2 installments. Fifty percent will vest six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date and will vest automatically as to 100% of the unvested portion of such restricted stock unit grant upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 17:34 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001209191-20-005410 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: This option was granted on January 27, 2020 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| July 25, 2019 Filed Jul 29, 2019 16:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantCommon Stock | 21,505 | $4.65 | $99,998.25 |
DisclosureSEC source: 0001209191-19-043485 · doc4.xml · nonDerivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,050 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 17:06 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $22.93 | $0.00 |
DisclosureSEC source: 0000899243-19-001957 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option was granted on January 23, 2019 and vests in four equal annual installments on the anniversary of the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events and the termination of the Reporting Person's employment under specified circumstances. Read SEC document |
| February 14, 2018 Filed Feb 15, 2018 20:29 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 203,858 | $0.00 Strike: $26.23 | $0.00 |
DisclosureSEC source: 0000899243-18-004343 · doc4.xml · derivative · entry 1 Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,858 Underlying: Common Stock · 203,858 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option shall vest in four equal installments beginning on February 14, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.